Pulse Biosciences, Inc. is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.
The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions. The CellFX System has received FDA 510(k) clearance and CE Mark approval in Europe, enabling commercial sales in the United States and select international markets. Beyond dermatology, Pulse Biosciences is exploring the NPS platform’s potential in oncology, immuno-oncology, wound healing and bacterial decontamination—areas that could benefit from nonthermal cellular disruption.
Founded in 2013 and headquartered in Hayward, California, Pulse Biosciences operates in North America and Europe, working closely with key opinion leaders in dermatology and medical research institutions. The company is led by President and Chief Executive Officer Vivek Chopra, who brings extensive experience in medical device development and commercialization. As Pulse Biosciences advances its clinical programs and expands its commercial footprint, it aims to establish TNP technology as a versatile tool across multiple therapeutic areas.
AI Generated. May Contain Errors.
Free PLSE Stock Alerts